Literature DB >> 8296486

Use of the Vibrio cholerae irgA gene as a locus for insertion and expression of heterologous antigens in cholera vaccine strains.

J R Butterton1, S A Boyko, S B Calderwood.   

Abstract

Vibrio cholerae may be a particularly effective organism for use in delivering heterologous antigens to stimulate a common mucosal immune response. A live attenuated vaccine strain of V. cholerae was constructed from the ctxA deletion mutant 0395-N1, containing the B subunit of Shiga-like toxin I under the transcriptional control of the iron-regulated irgA promoter. The B subunit of Shiga-like toxin I is identical to the B subunit of Shiga toxin (StxB). irgA encodes the major iron-regulated outer membrane protein of V. cholerae, which is a known virulence factor for this organism. Clones of the structural gene irgA from the classical V. cholerae strain 0395, with the gene for the Shiga-like toxin I B subunit inserted under the control of the irgA promoter, were used to introduce an internal deletion of irgA into the chromosome of 0395-N1 by in vivo marker exchange, using the suicide vector plasmid pCVD442. This plasmid contains the sacB gene from Bacillus subtilis, which allowed positive selection for loss of plasmid sequences on exposure to sucrose. The construction of vaccine strains was confirmed by Southern hybridization studies and outer membrane protein analysis. The expression of StxB in the vaccine strain VAC2 following growth in high- or low-iron conditions was shown to be tightly iron-regulated by Western blot analysis and by quantification of StxB using a sandwich enzyme-linked immunosorbent assay. The production of StxB by VAC2 under low-iron conditions was greater than that of the reference strain Shigella dysenteriae 60R.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8296486     DOI: 10.1016/0264-410x(93)90103-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

Review 1.  Detection and analysis of gene expression during infection by in vivo expression technology.

Authors:  D S Merrell; A Camilli
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-05-29       Impact factor: 6.237

2.  Optimizing the germfree mouse model for in vivo evaluation of oral Vibrio cholerae vaccine and vector strains.

Authors:  T I Crean; M John; S B Calderwood; E T Ryan
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 3.  Counterselectable markers: untapped tools for bacterial genetics and pathogenesis.

Authors:  J M Reyrat; V Pelicic; B Gicquel; R Rappuoli
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

4.  Development of a germfree mouse model of Vibrio cholerae infection.

Authors:  J R Butterton; E T Ryan; R A Shahin; S B Calderwood
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

5.  Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain.

Authors:  E T Ryan; J R Butterton; R N Smith; P A Carroll; T I Crean; S B Calderwood
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

6.  Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice.

Authors:  E T Ryan; J R Butterton; T Zhang; M A Baker; S L Stanley; S B Calderwood
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

7.  Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains.

Authors:  J R Butterton; E T Ryan; D W Acheson; S B Calderwood
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

8.  Markerless deletions of pil genes in Myxococcus xanthus generated by counterselection with the Bacillus subtilis sacB gene.

Authors:  S S Wu; D Kaiser
Journal:  J Bacteriol       Date:  1996-10       Impact factor: 3.490

9.  Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108.

Authors:  Weili Liang; Shixia Wang; Fenggang Yu; Lijuan Zhang; Guoming Qi; Yanqing Liu; Shouyi Gao; Biao Kan
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

Review 10.  Exploiting cholera vaccines as a versatile antigen delivery platform.

Authors:  Anisia J Silva; Francis O Eko; Jorge A Benitez
Journal:  Biotechnol Lett       Date:  2007-11-16       Impact factor: 2.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.